OncoMatch/Clinical Trials/NCT07156565
Actinium Therapy for Late-stage Aggressive Sarcomas
Is NCT07156565 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies [Ac 225]RTX-2358 for advanced soft tissue sarcoma.
Treatment: [Ac 225]RTX-2358 — The goal of this clinical trial is to learn about the safety of drug \[Ac225\]RTX-2358 and the diagnostic imaging agent \[Cu64\]LNTH-1363S. Additionally Ratio Therapeutics will learn if \[Ac225\]RTX-2358 drug is effective in treating advanced sarcoma. The main questions the study aims to answer in Phase/Part 1 of the trial are: * Is \[Ac225\]RTX-2358 tolerable or does it cause toxicities (medical problems) in patients. * What is the most tolerable dose of \[Ac225\]RTX-2358 * Does the treatment show effectiveness on advanced sarcoma Participants will: * Take drug \[Ac225\]RTX-2358 once every 8 weeks (4 cycle target; 6 cycle maximum) over a period of 12 months * Visit the clinic three times for the first week of cycle one, then once a week for the remaining 7 weeks of cycle 1 for check-ups and tests. * For cycles 2-6: patient will visit the clinic once every 2 weeks for checkups and tests * Remain in long term follow-up for a period of four additional years
Check if I qualifyExtracted eligibility criteria
Cancer type
Sarcoma
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: whole pelvic irradiation
History of whole pelvic irradiation.
Cannot have received: radioligand therapy
History of radioligand therapy.
Cannot have received: palliative surgery or external beam radiation
Exception: within 14 days prior to first administration
Treatment within 14 days prior to first administration with: Palliative surgery or external beam radiation.
Cannot have received: approved anticancer therapy including chemotherapy or immunotherapy
Exception: within 14 days prior to first administration
Treatment within 14 days prior to first administration with: Approved anticancer therapy including chemotherapy or immunotherapy.
Cannot have received: investigational therapy
Exception: within 14 days prior to first administration
Treatment within 14 days prior to first administration with: Any investigational therapy.
Cannot have received: major surgery
Exception: within 14 days prior to first administration
Treatment within 14 days prior to first administration with: Any major surgery (e.g., requiring general anesthesia).
Lab requirements
Blood counts
Neutrophil count ≥ 1200 µL without G-CSF; Platelet count ≥ 100,000 µL; Hemoglobin ≥ 8 g/dL; Coagulation parameters (PT, INR, aPTT) ≤ 1.5 × ULN
Kidney function
Calculated creatinine clearance ≥ 60 mL/min
Liver function
Total bilirubin level ≤ 1.5 × ULN; AST and ALT ≤ 2.5 × ULN
Adequate Organ reserve and renal function as evidenced by: Neutrophil count ≥ 1200 µL without granulocyte colony stimulating factor; Platelet count ≥ 100,000 µL; Hemoglobin ≥ 8 g/dL; Total bilirubin level ≤ 1.5 × ULN; AST and ALT ≤ 2.5 × ULN; Calculated creatinine clearance ≥ 60 mL/min; Coagulation parameters (PT, INR, aPTT) ≤ 1.5 × ULN
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- UCLA · Los Angeles, California
- Mayo Clinic · Rochester, Minnesota
- Memorial Sloane Kettering Cancer Center · New York, New York
- Case Western · Cleveland, Ohio
- MD Anderson Cancer Center · Houston, Texas
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify